Cargando…
OP12 Durability and immunogenicity after two doses of ChAdOx1 nCov-19 among the type of cancer treatment in oncologic patients: A prospective, multicenter observational study
Autores principales: | Wanchaijiraboon, P., Teeyapun, N., Luangdilok, S., Wanlapakorn, N., Sainamthip, P., Pakvisal, N., Namkanisorn, T., Sriuranpong, V., Phaibulvatanapong, E., Veranitinun, R., Inthasuwan, P., Sartsuk, C., Phongwan, R., Angspatt, P., Wongchanapat, P., Poovorawan, Y., Tanasanvimon, S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Published by Elsevier Ltd
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9802649/ http://dx.doi.org/10.1016/j.esmoop.2022.100695 |
Ejemplares similares
-
Immunogenicity of ChAdOx1-nCoV-19 vaccine in solid malignancy patients by treatment regimen versus healthy controls: A prospective, multicenter observational study
por: Teeyapun, Nattaya, et al.
Publicado: (2022) -
Vaccine-Related adverse events following AZD1222 (ChAdOx1-nCoV-19) Covid-19 vaccine in solid malignancy patients receiving cancer treatment, as compared to age-matched healthy controls
por: Pakvisal, Nussara, et al.
Publicado: (2022) -
Durability of Immune Response to ChAdOx1-nCoV-19 Vaccine in Solid Cancer Patients Undergoing Anticancer Treatment
por: Wanchaijiraboon, Passakorn, et al.
Publicado: (2022) -
Safety Following COVID-19 Booster Vaccine with BNT162b2 Compared to mRNA-1273 in Solid Cancer Patients Previously Vaccinated with ChAdOx1 or CoronaVac
por: Wanchaijiraboon, Passakorn, et al.
Publicado: (2023) -
Immunogenicity after a Third COVID-19 mRNA Booster in Solid Cancer Patients Who Previously Received the Primary Heterologous CoronaVac/ChAdOx1 Vaccine
por: Luangdilok, Sutima, et al.
Publicado: (2022)